Why the study?
Do zotarolimus-eluting stents perform similarly to contemporary second-generation stents in patients with coronary syndromes?
Do zotarolimus-eluting stents perform similarly to contemporary second-generation stents in patients with coronary syndromes?
Zotarolimus-eluting stents (Resolute family) demonstrate similar performance to other contemporary second-generation drug-eluting stents in percutaneous coronary intervention.
Supports zotarolimus-eluting stent use as comparable alternatives in PCI; reinforces equivalence among contemporary second-generation DES.
Drug-eluting stents revolutionized the treatment of coronary artery disease with vastly improved outcomes compared with bare metal stents. As stent technology has evolved, a wide variety of antiproliferative drugs have been developed to prevent stent restenosis and stent thrombosis. The Resolute stent system (Medtronic, CA, USA) elutes zotarolimus from a multipolymer blend to prevent early and late stent-related complications. The Resolute stents have evolved from the initial Resolute stent, to the Resolute Integrity™ and most recently, the Resolute Onyx™. These stents have been studied across a wide range of patients and coronary syndromes. They compare similarly in performance to their contemporary second generation stents. We present a review of the major trials involving these zotarolimus-eluting stents.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: